1. Academic Validation
  2. Ceramide structural features required to stimulate ABCA1-mediated cholesterol efflux to apolipoprotein A-I

Ceramide structural features required to stimulate ABCA1-mediated cholesterol efflux to apolipoprotein A-I

  • J Lipid Res. 2006 Dec;47(12):2781-8. doi: 10.1194/jlr.M600380-JLR200.
Amy B Ghering 1 W Sean Davidson
Affiliations

Affiliation

  • 1 Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH 45237-0507, USA.
Abstract

Ceramide is a component of the sphingomyelin cycle and a well-established lipid signaling molecule. We recently reported that ceramide specifically increased ABCA1-mediated Cholesterol efflux to apolipoprotein A-I (apoA-I), a critical process that leads to the formation of cardioprotective HDL. In this report, we characterize the structural features of ceramide required for this effect. C2 dihydroceramide, which contains a fully saturated acyl chain and is commonly used as a negative control for ceramide apoptotic signaling, stimulated a 2- to 5-fold increase in ABCA1-mediated Cholesterol efflux to apoA-I over a 0-60 muM concentration range without the cell toxicity apparent with native C2 ceramide. Compared with C2 ceramide, C6 and C8 ceramides with medium-length N-acyl chains showed a similar extent of efflux stimulation (a 2- to 5-fold increase) but at a higher onset concentration than the less hydrophobic C2 ceramide. In contrast, the reduced and methylated ceramide analogs, N,N-dimethyl sphingosine and N,N,N-trimethyl sphingosine, failed to stimulate Cholesterol efflux. We found that changes in the native spatial orientation at either of two chiral carbon centers (or both) resulted in an approximately 50% decrease compared with native ceramide-stimulated Cholesterol efflux. These data show that the overall ceramide shape and the amide bond are critical for the Cholesterol efflux effect and suggest that ceramide acts through a protein-mediated pathway to affect ABCA1 activity.

Figures
Products